Regeneron Pharmaceuticals EV/EBIT REGN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 20.0×
10-year median: 17.3×
Against its 10-year history: 68th; percentile: 0 is its lowest day, 100 its highest
10-year range: 6.4× to 38.0×
Peer median: 22.4×

Regeneron Pharmaceuticals' EV/EBIT is 20.0× as of Oct 23, 2026.

That is above its ten-year median of 17.3×, higher than on 68% of days in the last ten years.

Over that time it ranged from 6.4× in Jun 2022 to 38.0× in Jun 2017.

The median for 10 biotech stocks of a similar size is 22.4×.

EV/EBIT over time

median 17.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.0×	15.8×	21.9×
2025	20.6×	12.2×	20.6×
2024	17.7×	17.4×	31.8×
2023	20.8×	11.4×	20.8×
2022	11.4×	6.4×	12.2×
2021	8.6×	8.3×	18.3×
2020	16.4×	15.5×	28.5×
2019	17.2×	12.1×	19.1×
2018	16.0×	13.8×	21.6×
2017	21.0×	20.9×	38.0×
2016	31.0×	27.1×	41.0×
2015	45.3×	44.6×	62.1×
2014	50.6×	34.9×	52.4×
2013	39.6×	34.1×	65.6×
2012	60.9×	51.2×	65.5×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
REGNRegeneron Pharmaceuticals	20.0×
VRTXVertex Pharmaceuticals	26.6×
ONCBeOne Medicines	42.2×
ALNYAlnylam Pharmaceuticals	27.9×
UTHRUnited Therapeutics	16.1×
INCYIncyte	10.1×
EXELExelixis	15.4×
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
TECHBIO-TECHNE	44.9×
RGENRepligen	160×
Peer median	22.4×

Where Regeneron Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.